Abstract
There has been increased interest in the role of anti-Proteus antibodies in the aetiology of rheumatoid arthritis (RA) and whether chemotherapeutic agents active against Proteus species might reduce the risk and/or exacerbations of RA. We examined the in vitro antibacterial effects of ten different silver preparations which were either ionic silver [Ag(I)] solutions or nanoparticulate silver (NPS) (Ag0) suspensions against ATCC and two wild (clinical) strains of Proteus. The data establish the low minimum inhibitory concentration and minimum bactericidal concentration of all the silver formulations tested against these four Proteus strains. In a pilot study, a potent NPS preparation ex vivo showed long-lasting anti-Proteus activity in a normal human volunteer.
References
Chandler RW, Robinson H, Masi AT (1971) Serological investigations for evidence of an infectious aetiology of rheumatoid arthritis. Ann Rheum Dis 30:274–278
Cock I, van Vuuren SF (2013) Anti-Proteus activity of some South African medicinal plants: their potential for the prevention of rheumatoid arthritis. Inflammopharmacology. doi:10.1007/s10787-013-0179-3
Cock I, Mohanty S, White A, Whitehouse M (2012) Colloidal silver (CS) as an antiseptic: two opposing viewpoints. Pharmacog Comm 2:47–56
Dayanand S, Dayanand A, Sreedhar B, Dastager SG (2010) Antimicrobial activity of silver nanoparticles synthesized from novel Streptomyces species. Dig J Nanomater Bios 5:447–451
Deighton CM, Gray J, Bint AJ, Walker DJ (1992a) Anti-Proteus antibodies in rheumatoid arthritis same-sexed sibships. Br J Rheumatol 31:241–245
Deighton CM, Gray SW, Bint AJ, Walker DJ (1992b) Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis 51:1206–1207
Ebringer A (2012) Rheumatoid arthritis and Proteus. Springer, London, p 223
Ebringer A, Rashid T, Wilson C (2003) Rheumatoid arthritis: proposal for the use of antimicrobial therapy in early cases. Scand J Rheumatol 32:2–11
Eckhardt S, Brunetto PS, Gagnon J, Prieve M, Geise B, Fromm KM (2013) Nanobio Silver: its interactions with peptides and bacteria, and its uses in medicine. Chem Rev 113:4708–4754
Fairley KF, Carson NE, Gutch RC, Leighton PO, Grounds AD, Laird EC et al (1971) Site of infection in acute urinary tract infection in general practice. Lancet 2:615
Ferrara P, Romaniello L, Vitelli O, Gatto A, Serva M, Cataldi L (2009) Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children. Scand J Urol Nephrol 43:369–372
Kim JS, Kuk E, Yu KN, Kim J, Park SJ, Lee HJ et al (2007) Antimicrobial effects of silver nanoparticles. Nanomedicine 3:95–101
Laroo H (2013) Colloidal nanosilver—its production method, properties, standards, and its bio-efficacy as an inorganic antibiotic. J Phys Chem Biophys (Omicsonline.org ISSN: 2161-0398)
Lee H, Ko KS, Song JH, Peck KR (2011) Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea. Microb Drug Resist 17:37–45
Liu J, Sonshine DA, Shervani S, Hurt RH (2010) Controlled release of biologically active silver from nanosilver surfaces. NANO 4:6903–6913
Lo B (2010) Ethical issues in clinical research: a practical guide. Walters Kluwer, Philadelphia, p 292
Marambio-Jones C, Hoek EMV (2010) A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J Nanopart Res 12:1531–1551
O’Hara CM, Brenner FW, Miller JM (2000) Classification, identification and clinical significance of Proteus, Providencia and Morganella. Clin Microbiol Rev 13:534–546
Rashid T, Ebringer A (2007) Rheumatoid arthritis is linked to Proteus—the evidence. Clin Rheumatol 26:1036–1043
Rashid T, Ebringer A (2011) Rheumatoid arthritis is caused by asymptomatic Proteus urinary tract infections. In: Nikibakhsh A (ed) Clinical management of complicated urinary tract infection. In-Tech. vol 11
Rashid T, Tiwana H, Wilson C, Ebringer A (2001) Rheumatoid arthritis as an autoimmune disease caused by Proteus urinary tract infections: a proposal for a therapeutic protocol. Israeli Med Assoc J (IMAJ) 3:675–680
Senior BW, Anderson GA, Morley KD, Ma Kerr (1999) Evidence that patients with rheumatoid arthritis have asymptomatic ‘non-significant’ Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect 8:99–106
Sylver N (2009) Handbook of frequency therapy. Desert Gate, Phoenix, p 732
Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A (1996) Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheum 35:592–594
Varner K, El-Badaway A, Feldhake D, Venkatapathy R (2010) State of the science literature review: everything nanosilver and more. US Environmental Protection Agency, Washington DC, p 363
Whitehouse M, Butters D, Vernon-Roberts B (2013) Conditional pharmacology/toxicology V: ambivalent effects of thiocyanate upon the development and the inhibition of experimental arthritis in rats by aurothiomalate (MyocrysinR) and metallic silver. Inflammopharmacology 21:291–300
Wilson C, Thakore D, Isenberg D, Ebringber A (1997) Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. Rheumatol Int 16:187–189
Xiu Z-M, Zhang Q-B, Puppala HL, Colvin VL, Alvarez PJJ (2012) Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett 12:4271–4275
Acknowledgments
We are indebted to A White and J Petty for advice and assistance with silver analyses; to M Baharevs (Sydney) and Academician V Nesterov (Omsk) for assistance and advice in using the MetAtron monitor; to Dr G Maas (USA) for providing Meso Silver; and to D Butters for preparing the final MS. The Brisbane Holland Park Lions Club and W Whitney (and friends) helped fund the NPS studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Disaanayake, D.M.B.T., Faoagali, J., Laroo, H. et al. Efficacy of some colloidal silver preparations and silver salts against Proteus bacteria, one possible cause of rheumatoid arthritis. Inflammopharmacol 22, 73–77 (2014). https://doi.org/10.1007/s10787-013-0198-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-013-0198-0